IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
Phase 1 biotech developing inhibitor therapies for oncogene amplified tumors.
Industry: Health Care
Latest Trade: $8.59 0.00 (0.0%)
First Day Return: -10.9%
Return from IPO: -46.3%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 03/06/2024 |
Offer Price | $16.00 |
Price Range $15.00 - $17.00 | |
Offer Shares (mm) | 6.3 |
Deal Size ($mm) | $100 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 03/27/2024 |
Offer Price | $16.00 |
Price Range $15.00 - $17.00 | |
Offer Shares (mm) | 6.3 |
Deal Size ($mm) | $100 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
Goldman Sachs |
Leerink Partners |
more |
Company Data | |
---|---|
Headquarters | San Diego, CA, United States |
Founded | 2018 |
Employees | 72 |
Website www.boundlessbio.com |